Related Experiment Video
Updated: Aug 23, 2025
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on
Konstantinos G Kyriakoulis1, Evangelos Dimakakos1, Ioannis G Kyriakoulis1
1Third Department of Medicine, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Insights
Pharmacologic thromboprophylaxis is recommended for hospitalized COVID-19 patients to reduce venous thromboembolism (VTE) and mortality. Dosing varies by severity, and post-discharge use should be individualized for high-risk patients.
Area of Science:
- Medical Research
- Cardiology
- Infectious Diseases
Background:
- COVID-19 significantly increases the risk of venous thromboembolism (VTE) in both hospitalized and outpatient settings.
- Pharmacologic thromboprophylaxis has demonstrated benefits in reducing VTE events and mortality, particularly in acutely ill COVID-19 patients.
Purpose of the Study:
- To systematically review randomized controlled trials (RCTs) on thromboprophylaxis strategies for COVID-19 patients.
- To provide evidence-based guidance for clinical practice regarding thromboprophylaxis in different patient settings.
Main Methods:
- Systematic review of 20 randomized controlled trials (RCTs).
- Analysis of evidence for thromboprophylaxis in inpatient and outpatient COVID-19 settings.
- Development of practical recommendations based on RCT data.
Main Results:
- Thromboprophylaxis is recommended for all hospitalized COVID-19 patients with acceptable bleeding risk.
- Optimal inpatient thromboprophylaxis dosage depends on COVID-19 severity.
- Post-discharge thromboprophylaxis should be individualized for high-risk COVID-19 patients.
- Routine thromboprophylaxis is not recommended for outpatients with COVID-19.
Conclusions:
- Hospitalized COVID-19 patients benefit from thromboprophylaxis.
- Individualized risk assessment is crucial for post-discharge thromboprophylaxis decisions.
- Future research is needed to address evolving patient characteristics and therapeutic strategies.
Abstract:
Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in the outpatient setting. Pharmacologic thromboprophylaxis has been shown to offer significant benefits in terms of reducing not only VTE events but also mortality, especially in acutely ill patients with COVID-19. Although the main source of evidence is derived from observational studies with several limitations, thromboprophylaxis is currently recommended for all hospitalized patients with acceptable bleeding risk by all national and international guidelines. Recently, high quality data from randomized controlled trials (RCTs) further support the role of thromboprophylaxis and provide insights into the optimal thromboprophylaxis strategy. The aim of this statement is to systematically review all the available evidence derived from RCTs regarding thromboprophylaxis strategies in patients with COVID-19 in different settings (either inpatient or outpatient) and provide evidence-based guidance to practical questions in everyday clinical practice. Clinical questions accompanied by practical recommendations are provided based on data derived from 20 RCTs that were identified and included in the present study. Overall, the main conclusions are: (i) thromboprophylaxis should be administered in all hospitalized patients with COVID-19, (ii) an optimal dose of inpatient thromboprophylaxis is dependent upon the severity of COVID-19, (iii) thromboprophylaxis should be administered on an individualized basis in post-discharge patients with COVID-19 with high thrombotic risk, and (iv) thromboprophylaxis should not be routinely administered in outpatients. Changes regarding the dominant SARS-CoV-2 variants, the wide immunization status (increasing rates of vaccination and reinfections), and the availability of antiviral therapies and monoclonal antibodies might affect the characteristics of patients with COVID-19; thus, future studies will inform us about the thrombotic risk and the optimal therapeutic strategies for these patients.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies